MADISON, Wis.--(BUSINESS WIRE)-- Exact Sciences Corporation (EXAS) (“Exact Sciences”), a leading provider of cancer screening and diagnostic tests, today announced that its stockholders voted to ...
MADISON, Wis., February 20, 2026--(BUSINESS WIRE)--Exact Sciences Corporation (NASDAQ: EXAS) ("Exact Sciences"), a leading provider of cancer screening and diagnostic tests, today announced that its ...
Total fourth quarter revenue of $878 million, an increase of 23% on a reported and core revenue basis, with Screening revenue of $695 million and Precision Oncology revenue of $183 million Total 2025 ...
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today celebrated the passage of landmark federal legislation that ...
Abstract: Background: In this study, we examined the effectiveness of three instruction-production arrangements: instruction-problem solving (I-PS), problem solving-instruction (PS-I), and problem ...
Abbott Laboratories ABT-0.97%decrease; red down pointing triangle agreed to acquire cancer diagnostics company Exact Sciences EXAS-0.07%decrease; red down pointing triangle in a deal valued at about ...
Abbott said on Thursday it would buy cancer test maker Exact Sciences in an up to $23 billion deal, bolstering the medical device maker's diagnostics business. This marks one of Abbott's largest deals ...
In January, Exact Sciences CEO Kevin Conroy told us that 2025 was shaping up to be a transformative year for the diagnostics company. Three cancer test launches, multiple study readouts and one $23 ...
Abbott is acquiring Exact Sciences for $23 billion, the global healthcare leader announced on Thursday. Exact Sciences shareholders will receive $105 per common share, totaling approximately $21 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results